Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
545 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05312671 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | recruiting | Phase 2 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05716009 | Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML(GO-TAG) | terminated | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Jun 25, 2026 |
| clinicaltrials |
| NCT06922318 | The COSMYC Trial (COmbined Suppression of MYC) | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07375992 | Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)(MELODY) | recruiting | N/A | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04658147 | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 1 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05025423 | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma | terminated | Phase 2 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02965755 | Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins(IMAGE-II) | active not recruiting | N/A | 200 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02738866 | Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03918252 | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | active not recruiting | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04753879 | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | active not recruiting | Phase 2 | 38 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02451982 | Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas | active not recruiting | Phase 2 | 76 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01135329 | Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | terminated | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03237377 | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT04019964 | Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | completed | Phase 2 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT01937039 | Johns Hopkins Breast Cancer Program Longitudinal Repository | active not recruiting | — | 810 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04848116 | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca(Spark2) | active not recruiting | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03047135 | Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis | active not recruiting | Phase 2 | 51 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03767582 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06564623 | Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) | recruiting | Phase 1 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03610711 | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer(REACTION) | active not recruiting | Phase 1 / Phase 2 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06205836 | Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer | recruiting | Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07512154 | Precision Radiotherapy Enabled by Molecular MRI | recruiting | N/A | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03521830 | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | recruiting | Phase 2 | 57 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05014776 | Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer | completed | Phase 2 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03961971 | Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM | active not recruiting | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)((NeoScorch HN)) | recruiting | Phase 2 | 75 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05917301 | Pre-operative Hypofractionated Proton Therapy(PRONTO) | recruiting | N/A | 40 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02845323 | Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder | active not recruiting | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06803745 | Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT) | recruiting | N/A | 160 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06376669 | Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma(SPARE) | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04713046 | Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers | active not recruiting | Phase 1 / Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03471650 | Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer | active not recruiting | Phase 2 | 150 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03786796 | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations(ORCHID) | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05254184 | KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC | recruiting | Phase 1 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06389097 | SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization((SEEtoTREAT)) | recruiting | — | 80 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07071155 | Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia(M-HArbOr) | recruiting | Early Phase 1 | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03044613 | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03607890 | Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | active not recruiting | Phase 2 | 38 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT01804634 | Reduced Intensity Haploidentical BMT for High Risk Solid Tumors | recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02648282 | Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | 58 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04301778 | Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07142551 | Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response | recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06508138 | Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection(J21112LINKED) | enrolling by invitation | Phase 1 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00616967 | Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer | active not recruiting | Phase 2 | 68 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04243473 | Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04988074 | Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca(MINIMA) | recruiting | Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06836648 | Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer | available | — | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT01203722 | Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | completed | Phase 1 / Phase 2 | 87 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06616597 | Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer | recruiting | Phase 2 | 58 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 19, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials